Sichuan Kelun Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. It operates through Twinings, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detaine… Read more
Market Cap & Net Worth: Sichuan Kelun Pharmaceutical Co Ltd (002422)
Sichuan Kelun Pharmaceutical Co Ltd (SHE:002422) has a market capitalization of $7.48 Billion (CN¥54.88 Billion) as of April 8, 2026. Listed on the SHE stock exchange, this China-based company holds position #2707 globally and #173 in its home market, demonstrating a -1.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sichuan Kelun Pharmaceutical Co Ltd's stock price CN¥34.34 by its total outstanding shares 1598053372 (1.60 Billion).
Sichuan Kelun Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Sichuan Kelun Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $3.50 Billion to $7.48 Billion (8.96% CAGR).
Sichuan Kelun Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sichuan Kelun Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.30x
Sichuan Kelun Pharmaceutical Co Ltd's market cap is 0.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.22x
Sichuan Kelun Pharmaceutical Co Ltd's market cap is 2.22 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.50 Billion | $7.76 Billion | $645.27 Million | 0.45x | 5.43x |
| 2016 | $3.06 Billion | $8.57 Billion | $584.64 Million | 0.36x | 5.24x |
| 2017 | $4.77 Billion | $11.43 Billion | $748.54 Million | 0.42x | 6.38x |
| 2018 | $3.99 Billion | $16.35 Billion | $1.21 Billion | 0.24x | 3.29x |
| 2019 | $4.57 Billion | $17.64 Billion | $937.86 Million | 0.26x | 4.87x |
| 2020 | $3.86 Billion | $16.46 Billion | $829.39 Million | 0.23x | 4.65x |
| 2021 | $3.82 Billion | $17.28 Billion | $1.10 Billion | 0.22x | 3.46x |
| 2022 | $5.50 Billion | $19.04 Billion | $1.71 Billion | 0.29x | 3.22x |
| 2023 | $6.12 Billion | $21.45 Billion | $2.46 Billion | 0.29x | 2.49x |
| 2024 | $6.52 Billion | $21.81 Billion | $2.94 Billion | 0.30x | 2.22x |
Competitor Companies of 002422 by Market Capitalization
Companies near Sichuan Kelun Pharmaceutical Co Ltd in the global market cap rankings as of April 8, 2026.
Key companies related to Sichuan Kelun Pharmaceutical Co Ltd by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $831.54 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $573.52 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #34 globally with a market cap of $364.26 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #43 globally with a market cap of $302.23 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $831.54 Billion | $931.09 |
| #18 | Johnson & Johnson | NYSE:JNJ | $573.52 Billion | $238.41 |
| #34 | AbbVie Inc | NYSE:ABBV | $364.26 Billion | $206.37 |
| #43 | AstraZeneca PLC | NASDAQ:AZN | $302.23 Billion | $200.81 |
Sichuan Kelun Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Sichuan Kelun Pharmaceutical Co Ltd's market cap moved from $3.50 Billion to $ 7.48 Billion, with a yearly change of 8.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥7.48 Billion | +17.00% |
| 2025 | CN¥6.39 Billion | -1.94% |
| 2024 | CN¥6.52 Billion | +6.44% |
| 2023 | CN¥6.12 Billion | +11.41% |
| 2022 | CN¥5.50 Billion | +43.92% |
| 2021 | CN¥3.82 Billion | -0.98% |
| 2020 | CN¥3.86 Billion | -15.53% |
| 2019 | CN¥4.57 Billion | +14.56% |
| 2018 | CN¥3.99 Billion | -16.50% |
| 2017 | CN¥4.77 Billion | +55.81% |
| 2016 | CN¥3.06 Billion | -12.50% |
| 2015 | CN¥3.50 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 8th, 2026 the market cap of Sichuan Kelun Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.48 Billion USD |
| MoneyControl | $7.48 Billion USD |
| MarketWatch | $7.48 Billion USD |
| marketcap.company | $7.48 Billion USD |
| Reuters | $7.48 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.